ID

33387

Descrizione

Study ID: 104065 Clinical Study ID: 104065 Study Title: Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00169442  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completet Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT) Trade Name: Zilbrix/Hib Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Keywords

  1. 07/12/18 07/12/18 -
Titolare del copyright

GSK group of companies

Caricato su

7 dicembre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Immune memory of Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine at infants (15 to 18 mths) - 104065

Contraindications and Elimination Criteria

Administrative data
Descrizione

Administrative data

Subject Number
Descrizione

Subject Number

Tipo di dati

integer

Protocol Number
Descrizione

Protocol Number

Tipo di dati

integer

Date of Visit
Descrizione

Date of Visit

Tipo di dati

date

Elimination Criteria during the Study
Descrizione

Elimination Criteria during the Study

The criteria should be checked at each visit subsequent to the first visit.
Descrizione

If any become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis.

Tipo di dati

text

Contraindications to Subsequent Vaccination
Descrizione

Contraindications to Subsequent Vaccination

Contraindications to administration of the study vaccines at that point in time
Descrizione

if any one of these AE occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.

Tipo di dati

text

Similar models

Contraindications and Elimination Criteria

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Administrative data
Subject Number
Item
Subject Number
integer
Protocol Number
Item
Protocol Number
integer
Date of Visit
Item
Date of Visit
date
Item Group
Elimination Criteria during the Study
Item
The criteria should be checked at each visit subsequent to the first visit.
text
Code List
The criteria should be checked at each visit subsequent to the first visit.
CL Item
Use of any investigational or non-registered product (drug or vaccine) other that the study vaccine(s) during the study period. (1)
CL Item
Chronic administration (defined as more that 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, >=0.5 mg/kg/day. Inhaled and topical steroids are allowed.) (2)
CL Item
Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before administration of the study vaccine and ending 30 days after, with the exception of OPV. (3)
CL Item
Administration of immunoglobulins and/or any blood products during the study period. (4)
Item Group
Contraindications to Subsequent Vaccination
Item
Contraindications to administration of the study vaccines at that point in time
text
Code List
Contraindications to administration of the study vaccines at that point in time
CL Item
Acute disease at the time of vaccination: the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature <37.5°C / rectal temperature <38°C. (1)
CL Item
Axillary temperature >= 37.5°C / rectal temperature >=38°C at the time of booster vaccination. (2)

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial